Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

Lorenz Jahn, Renate S. Hagedoorn, Pleun Hombrink, PhD, Michel G.D. Kester, Dirk M. van der Steen, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD

Blood (2015) 126 (23): 3002.

https://doi.org/10.1182/blood.V126.23.3002.3002

Published: 2015

Journal Articles

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

Lorenz Jahn, Pleun Hombrink, Chopie Hassan, Michel G. D. Kester, Dirk M. van der Steen, Renate S. Hagedoorn, J. H. Frederik Falkenburg, Peter A. van Veelen, Mirjam H. M. Heemskerk

Blood (2015) 125 (6): 949–958.

https://doi.org/10.1182/blood-2014-07-587840

Published: 2015

Includes: Supplemental data

Journal Articles

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

Lorenz Jahn, Pleun Hombrink, Michel G.D. Kester, Dirk M. van der Steen, Renate S. Hagedoorn, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD

Blood (2014) 124 (21): 3832.

https://doi.org/10.1182/blood.V124.21.3832.3832

Published: 2014

Journal Articles

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

Lorenz Jahn, Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Renate S. Hagedoorn, Dirk M. van der Steen, Marjolein P. Schoonakker, J.H. Frederik Falkenburg, MD PhD, Peter A. van Veelen, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2014) 124 (21): 3837.

https://doi.org/10.1182/blood.V124.21.3837.3837

Published: 2014

Journal Articles

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Pleun Hombrink, MSc, Chopie Hassan, Michel G.D. Kester, Cornelis A.M. van Bergen, J.H.F. Falkenburg, MD, PhD, Peter A. van Veelen, Mirjam H.M. Heemskerk, PhD

Blood (2011) 118 (21): 4038.

https://doi.org/10.1182/blood.V118.21.4038.4038

Published: 2011

NARROW

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Email alerts

ASH Publications

American Society of Hematology

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only